Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation Academic Article uri icon

Overview

MeSH Major

  • Aminophenols
  • Cystic Fibrosis
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Quinolones

abstract

  • This study to evaluate the safety and adverse-event profile of VX-770 showed that VX-770 was associated with within-subject improvements in CFTR and lung function. These findings provide support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis. (Funded by Vertex Pharmaceuticals and others; ClinicalTrials.gov number, NCT00457821.).

publication date

  • November 18, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3148255

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa0909825

PubMed ID

  • 21083385

Additional Document Info

start page

  • 1991

end page

  • 2003

volume

  • 363

number

  • 21